ADC Therapeutics SA (ADCT)
3.23
-0.06
(-1.82%)
USD |
NYSE |
Dec 08, 16:00
3.21
-0.02
(-0.62%)
After-Hours: 17:24
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 400.12M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 71.35% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.969 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -1.920 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.08% |
Profile
| ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland. |
| URL | http://www.adctherapeutics.com |
| Investor Relations URL | https://ir.adctherapeutics.com/ |
| HQ State/Province | Vaud |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 02, 2026 (est.) |
| Last Earnings Release | Nov. 10, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland. |
| URL | http://www.adctherapeutics.com |
| Investor Relations URL | https://ir.adctherapeutics.com/ |
| HQ State/Province | Vaud |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 02, 2026 (est.) |
| Last Earnings Release | Nov. 10, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |